CONTEXT: Summary article on the continuing interest and need for RWR, fuelled by the COVID pandemic.
IMPACT: Low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 5
1. “In some cases, this involved getting participant consent to link trial data with RWD from medical claims, electronic health records, and other sources to gain a more enriched view of treatment and outcomes.”
2. “As Bruno Villetelle, head of data and digital for Novartis, noted in a recent podcast, “RWD can be a complement to typical drug development programs by informing a selection of endpoints and the design and recruitment of studies, which can potentially accelerate timelines, reduce clinical trial costs, and increase the probability of success.””
3. “Throughout the pandemic, RWD analyses have played a key role in evaluating clinical trial findings as well as informing a deeper understanding of how various risk factors affect patient outcomes.”
4. “RELATED: Industry Voices—How real-world EHR data are enhancing our understanding of COVID-19. The tragic events of the past year brought heightened awareness to long-standing issues of racial and ethnic diversity and representation in clinical research.”
5. “Examples like this have sparked much-needed soul searching and led to concrete measures, such as a new set of FDA guidelines for improving diversity and inclusion in clinical trials, among which is the recommendation to leverage RWD “to promote more efficient recruitment of a diverse population.””
Source URL: https://www.fiercehealthcare.com/tech/industry-voices-harnessing-a-watershed-moment-for-real-world-data